Germline mutations of BRCA1 and BRCA2 predispose to hereditary breast-ovarian cancer syndrome. In Finland, 20 different BRCA1/2 mutations have been identified, and 13 of them are founder mutations that account for the vast majority of Finnish BRCA1/2 families. The purpose of our study was to determine the prevalence of BRCA1/2 mutations in unselected Finnish ovarian carcinoma patients and to evaluate the relationship between mutation carrier status and personal/family history of cancer. Two hundred and thirtythree patients were screened for all the 20 BRCA1/2 mutations known in the Finnish population. Additionally, a subgroup of patients with personal history of breast cancer and/or family history of breast and/or ovarian cancer was screened for novel BRCA1/2 mutations. Thirteen patients (5.6%) had mutations: eleven in BRCA1 and two in BRCA2. All the mutation-positive patients were carriers of the previously known Finnish BRCA1/2 mutations, and seven recurrent founder mutations accounted for 12 of the 13 mutations detected. A logistic regression analysis was used to determine the odds of mutation for ovarian carcinoma patients. The most significant predictor of a mutation was the presence of both breast and ovarian cancer in the same woman, but family history of breast cancer was also strongly related to mutation carrier status. Although BRCA1/2 mutation testing is not warranted in the general Finnish ovarian cancer patient population, patients who have also been diagnosed with breast cancer or have family history of breast or breast and ovarian cancer could benefit from referral to genetic counselling and mutation testing. European Journal of Human Genetics (2001) 9, 424 ± 430.
Introduction
Inherited mutations of BRCA1 and BRCA2 predispose to hereditary breast-ovarian cancer syndrome. The lifetime risk of ovarian carcinoma has been estimated to be *60% in BRCA1 mutation carriers 1 and *30% in BRCA2 mutation carriers. 2 However, these estimates were based on families with multiple cases of breast and/or ovarian cancer, and studies that have consisted of patients not selected for their strong family history have suggested considerably lower risks. 3 ± 5 Furthermore, the location of the mutation in BRCA1
and BRCA2 may affect cancer phenotype. 5 ± 7 A higher ovarian cancer risk, in relation to breast cancer risk, has been reported to be associated with mutations in the 5' end of the BRCA1 gene, 5, 6 and in exon 11 of BRCA2, in a region known as the ovarian cancer cluster region. 5, 7 Hundreds of distinct mutations, most of which are unique, have been identified throughout the entire coding sequences of both BRCA1 and BRCA2, 8 which makes large-scale mutation screening laborious. In certain ethnic groups and populations, the presence of individual, highly recurrent founder mutations facilitates mutation carrier detection. Among Ashkenazi Jews, three BRCA1/2 founder mutations have been found to be present in about 40% of unselected ovarian carcinoma patients. 4 In addition to the Ashkenazi Jews, the frequencies of BRCA1 and/or BRCA2 mutations have been studied thus far in the UK, Hungary, Iceland, Canada, and the US, where the mutation frequencies have been observed to be considerably lower (varying from 2 to 10% for BRCA1 and from 1 to 8% for BRCA2).
5,9 ± 17
In the Finnish population 20 different BRCA1/2 mutations have been identified. 18 ± 23 Thirteen of the mutations, six in BRCA1 and seven in BRCA2, are recurrent founder mutations that account for the vast majority of all mutations detected. Due to the high coverage of the multiple founders, the impact of both BRCA1 and BRCA2 mutations can be studied efficiently and reliably at the population level in Finland. In the present study, all BRCA1/2 mutations known in the Finnish population were screened in a series of 233 unselected ovarian carcinoma patients. Furthermore, novel mutations were screened in a subset of patients with personal history of breast cancer and/or family history of breast and/or ovarian cancer. Mutation carrier status was correlated with personal and family history of breast and ovarian cancer.
Patients and methods

Patients
The study group consisted of 233 women with invasive epithelial ovarian carcinoma treated at the Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland during the years 1989 ± 1998. The Finnish population is well represented in the Helsinki University Central Hospital region: a quarter of the Finns reside in the region, and because of recent migration patterns in Finland, the patients diagnosed in the Helsinki University Central Hospital have their ancestral origins throughout Finland. Altogether 573 invasive epithelial ovarian carcinoma patients were treated at the Department during the years 1989 ± 1998, and at the end of the year 1998, 220 of those patients were alive. After initial treatment the patients routinely attend the clinic at least once a year for a time period of 10 years. In conjunction with such visits during the years 1997 and 1998, a blood sample and a written informed consent were obtained from the patients. Information concerning family history of cancer was collected by questionnaire interviews. The cohort studied covers 91% of all epithelial ovarian carcinoma patients who were alive during the study period. 
Screening for new mutations
Protein truncation test (PTT) was used in screening BRCA1 exon 11 25 and BRCA2 exons 10 and 11 26 for new mutations in 38 patients who reported: (1) two or more 1st and/or 2nd degree relatives diagnosed with breast or ovarian cancer; (2) a 1st, 2nd, or 3rd degree relative with ovarian cancer; (3) a 1st degree relative with breast cancer; and/or (4) a 1st degree relative with both breast and ovarian cancer or had themselves been diagnosed with both cancers. In order to detect possible large genomic rearrangements and deletions in BRCA1, Southern analysis was performed on eleven patient samples and two healthy population control individuals. Genomic DNA (5 mg) was digested with EcoRI according to the supplier's protocol (New England Biolabs, Beverly, MA, USA). Complete digests were run on agarose gels and separated DNA was denatured and transferred to nylon membranes (Hybond-N + , Amersham Pharmacia Biotech, Uppsala, Sweden) according to the protocol published by Petrij-Bosch et al. 8, 27 The probes consisted of PCR products amplified from cloned DNA containing the complete BRCA1 cDNA (pcBRCA1-385, a kind gift from Dr Lawrence Brody, NHGRI, NIH, MD, USA) and purified with the Qiaquick PCR purification kit (Qiagen GmbH, Hilden, Germany). Probes 1, 2, and 3 were obtained with primers F(forward)5'-GATT-TATCTGCTCTTCGC-3' and R(reverse)5' -CTTGAC-CATTCTGCTCC-3' (nucleotides (nt) 123-1752), F5'-CTAACCAAACGGAGCAG-3' and R5'-AACAAGTGTTG-GAAGCAG-3' (nt 1726-3791), and F5'-TTCCCTGCTTCCAA-CAC-3' and R5'-TGCTACACTGTCCAACACC-3' (nt 3787-5648), respectively. Purified fragments were labelled with [a-32 P]dCTP using Rediprime DNA labelling system (Amersham Pharmacia Biotech) according to the supplier's protocol. Prehybridisation, hybridisation, and washing were carried out as described by Petrij-Bosch et al. 8, 27 Filters were exposed overnight to Hyperfilm MP autoradiography film (Amersham Pharmacia Biotech) at 7708C.
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Statistical methods
A logistic regression analysis was used to determine the odds of mutation for ovarian cancer patients using personal and family history variables as explanatory variables. Fisher's exact test was used to study the association between mutation carrier status and young age (550 years) at breast cancer onset.
Results and Discussion
Germline mutations of BRCA1/2 were detected in 13 (5.6%) of the 233 unselected Finnish ovarian carcinoma patients. Mutations detected and personal and family history of cancer of the mutation carriers are presented in Table 2 . No new mutations were identified in this study, and seven recurrent founder mutations accounted for 12 of the 13 mutations detected, emphasising the significance of the BRCA1/2 founder mutations in Finland. Thus about 5% of the ovarian carcinoma patients were carriers of the recurrent BRCA1/2 founder mutations. The only unique mutation had been identified previously 21 in the same patient that also belonged to the present study cohort. Large genomic deletions that have been identified as major BRCA1 founder mutations in the Netherlands 27 do not seem to be significant in the Finnish population; no such mutations were found among the 11 ovarian carcinoma patients studied here or in another study of 80 Finnish breast and/or ovarian cancer families (R Winqvist, personal communication).
In the Finnish ovarian carcinoma patient, the frequency of BRCA1 mutations (4.7%) was notably higher than the frequency of BRCA2 mutations (0.9%). In contrast, in a population-based study of 1035 unselected Finnish breast cancer patients, BRCA2 mutations were considerably more prevalent (with the frequency of 1.4%) than BRCA1 mutations (with the frequency of 0.4%). 22 Overall, BRCA1/2 mutations are more prevalent in unselected Finnish ovarian cancer (5.6%) than breast cancer patients (1.8%). The frequency of BRCA1/2 mutations (5.6%) in the Finnish ovarian carcinoma patients is far lower than in the Ashkenazi Jewish population where three highly recurrent BRCA1/2 founder mutations were detected in 41.3% (86/208) of unselected ovarian carcinomas. 4 Among French Canadians, few BRCA1 and BRCA2 founder mutations were found in 8.1% (8/99) of unselected ovarian carcinoma patients, 16 while in a population-based series of unselected Canadian ovarian carcinoma patients, 26 distinct BRCA1 and 19 distinct BRCA2 mutations were detected with the frequency of 7.6% (39/515) and 4.1% (21/515), respectively. 5 In the isolated Icelandic population, one strong BRCA2 founder mutation was present in 7.9% (3/38) of ovarian carcinomas, 15 and in Hungary, three BRCA1 founder mutations accounted for 11.1% (10/90) of unselected ovarian carcinoma patients, whereas none of the patients carried either of the two BRCA2 founder mutations known in the Hungarian population. 13 The frequencies of BRCA1 (4.7%) and BRCA2 (0.9%) the mutations in Finland are more similar to those reported in the UK and the US. 9 ± 12,14,17 In the screening for BRCA1 mutations, 1.9 ± 3.9% of unselected ovarian carcinoma patients were found to be mutation-positive in California and North Carolina. 9, 10, 12 In Pennsylvania, the frequency of BRCA1 mutations has been reported to be as high as 8.6%. 14 However, in that study the ethnicity of the patients was unknown, whereas in the other American studies Ashkenazi Jews were known not to be overrepresented. 9,10,12,14 BRCA2
mutations have been detected in 0.9 ± 3.1% of American ovarian carcinomas. 14, 17 In the UK, 3.5% (13/374) of unselected ovarian carcinoma patients were found to be mutation-positive in the screening for BRCA1 mutations.
11
The mutation detection sensitivity was estimated to be 70%, hence the true BRCA1 mutation frequency would be 5%.
The BRCA1/2 mutation frequency of 5.6% reported in our study obviously also represents an underestimate. New mutations were searched in a subset of patients with personal history of breast cancer and/or family history of breast and/or ovarian cancer, whereas all patients were screened for all 20 BRCA1/2 mutations known to be present in the Finnish population. We believe that our result is well representative of the BRCA1/2 mutation burden because founder mutations have been found to account for the vast majority of BRCA1/2 families in Finland. 18 ± 21 The significance of these founder mutations was also observed in this independent study. Ovarian carcinomas of high grade are typical for BRCA1/2 mutation carriers. 4 Such carcinomas were, however, slightly underrepresented in our study cohort (Table 1) ; thus the real mutation frequencies might be somewhat higher. However, the possible effects of retrospectively collected study cohort are hard to evaluate as contradictory results on survival of BRCA1/2 mutation carriers have been reported. In most populations BRCA1/2 mutations are relatively uncommon among ovarian cancer patients. Therefore, it is important to identify risk factors that predict the likelihood of finding a BRCA1/2 mutation, so that mutation screening could be directed to potential mutation carriers. 32 Among the 13 mutation carrier patients, 11 (85%) had a personal and/or family history of breast cancer (Table 2 ). Breast and ovarian cancer had been diagnosed in the same woman (index or a relative) in seven cases (54%), and also seven of the mutation carriers had a history of breast cancer diagnosed below the age of 50 years (index or a relative). Altogether, the presence of breast and ovarian cancer in the same woman and/or early onset (550 years) breast cancer was characteristic of the majority (77%) of the mutation carriers. When a logistic regression analysis was used to determine the odds of a BRCA1/2 mutation for ovarian carcinoma patients, the single most significant predictor of a mutation was the presence of both breast and ovarian cancer in the same patient (Table 3) . The odds ratio also independently increased for patients who reported at least two relatives with breast or ovarian cancer and for patients who reported one relative with breast cancer only ( Table 3 ). The likelihood of finding a mutation also increased when the age at breast cancer onset became younger (Table 4) . However, there was no statistically significant association between the mutation carrier status and young age (550 years) at breast cancer onset (P=0.40, Fisher's exact test). This may be due to the small number of breast cancer cases for which the information on the age at onset was available. In addition to personal and family history of breast and ovarian cancer, bilateral breast cancer, young age at breast cancer onset, and Ashkenazi Jewish descent have been reported to be predictive of a BRCA1 or BRCA2 mutation.
± 31
± 36
Ovarian cancer histology might also be predictive of BRCA1 mutations since almost all BRCA1-associated ovarian carcinomas have been reported to be of serous histology, 5, 11 while BRCA2 mutation carriers have been reported to have carcinomas of various histological subtypes. 17 In our study, all mutation-positive patients except for one had serous or poorly differentiated carcinoma (Table 4) . Of all serous carcinomas, BRCA1 mutation was found in 6.8% and BRCA2 mutation in 1.7%. None of the mutation carriers had a carcinoma of mucinous or endometrioid subtype. However, the tumour histology variable did not independently increase the odds of mutation in the logistic regression analysis. Since there is evidence that the molecular pathogenesis of various histological forms of ovarian carcinoma might be distinct, 37 it seems likely that somatic mutations that occur in association with the inactivation of the BRCA1 gene may lead to the serous subtype of ovarian carcinoma. No mutations were detected among the thirteen patients who reported one 1st or 2nd degree relative with ovarian cancer only (Table 4) . Also in the study of Gayther et al 38 BRCA1/2 mutations were detected in only 20% of families with two cases of ovarian cancer alone, while they were detected in 66% of families with either three or more cases of ovarian cancer or four or more cases of breast or ovarian cancer. A combination of chance clustering of sporadic cases, non-genetic familial factors, and incomplete sensitivity of mutation detection may account for a significant fraction of BRCA1/2 mutation-negative ovarian carcinoma families. However, still unidentified, possible low-penetrance genes may be important in some families. 39 Ovarian carcinoma also occurs as part of the hereditary nonpolyposis colorectal cancer syndrome (HNPCC), which is caused by germline mutations in DNA mismatch repair genes. 40 Mutations in these genes have been reported in 1.7% of unselected ovarian carcinoma patients. 14 Instability of several microsatellites, which is a characteristic of inherited mismatch repair system deficiency, 41, 42 ie HNPCC, has been detected in one out of 62 (1.6%) serous ovarian carcinomas in the present study cohort; 43 thus mutations in the genes that predispose to HNPCC are likely to account for only a small fraction of the ovarian carcinomas in our series.
In conclusion, BRCA1/2 founder mutations account for about 5% of ovarian carcinomas in Finland. Since screening of all ovarian carcinoma patients for BRCA1/2 mutations is not clinically and ethically justified, it is important to identify those women who have high probability of carrying a deleterious BRCA1/2 mutation. 32 Our results indicate that ovarian carcinoma patients who have also been diagnosed with breast cancer or have family history of breast or breast and ovarian cancer could benefit from referral to genetic counselling and mutation testing. 
